Anticoagulation and Venous Thromboembolism (VTE)
A comprehensive lecture note covering hemostasis, DVT and PE, anticoagulant classes, reversal strategies, HIT, peri-procedural management, and exam-focused VTE treatment decisions.
1. Learning Objectives
- Differentiate arterial and venous thrombosis and understand the coagulation cascade.
- Identify risk factors, signs, and symptoms of DVT and PE.
- Apply evidence-based VTE prophylaxis in hospitalized and surgical patients.
- Compare mechanisms, monitoring, pharmacokinetics, and adverse effects of anticoagulant classes.
- Select appropriate anticoagulant therapy based on renal function, cancer, pregnancy, and other patient-specific factors.
- Determine appropriate duration of anticoagulation based on provoking factors and recurrence risk.
- Manage anticoagulant-related bleeding and reversal agents appropriately.
- Recognize and manage heparin-induced thrombocytopenia.
- Provide patient-centered counseling on adherence, monitoring, and bleeding precautions.
2. Introduction to Hemostasis and Thrombosis
Hemostasis keeps blood fluid within vessels but allows clot formation when injury occurs. Thrombosis is pathologic clot formation within intact vessels, obstructing blood flow and creating embolic risk.
| Pathway | Activation Mechanism | Key Factors |
|---|---|---|
| Intrinsic | Exposure of blood to subendothelial collagen | XII, XI, IX, VIII |
| Extrinsic | Tissue factor release from damaged endothelium | VII |
| Common | Convergence at Factor X activation | X, V, II, I |
Regulatory anchors
- Vitamin K-dependent factors: II, VII, IX, X, proteins C and S
- Antithrombin inactivates thrombin and Factor Xa
- Heparin and fondaparinux work by potentiating antithrombin
Arterial vs venous thrombosis
- Arterial clots are platelet-rich and antiplatelet-responsive
- Venous clots are fibrin-rich and anticoagulant-responsive
- Venous thrombosis centers on stasis, hypercoagulability, and endothelial injury
3. Venous Thromboembolism
3.1. Deep Vein Thrombosis
- Usually occurs in lower-extremity deep veins
- Typical features: unilateral swelling, pain, warmth, erythema, tenderness
- Homan's sign is unreliable and not diagnostic
- Complications include post-thrombotic syndrome, recurrence, and PE
3.2. Pulmonary Embolism
- Usually originates from lower-extremity DVT
- Typical symptoms: sudden dyspnea, pleuritic chest pain, tachycardia, tachypnea, hemoptysis, syncope
- Signs of DVT may coexist
| PE Classification | Definition | Mortality Risk | Management |
|---|---|---|---|
| Massive (high-risk) | Hypotension, cardiogenic shock, or persistent hemodynamic instability | High | Thrombolysis or embolectomy plus anticoagulation |
| Submassive (intermediate-risk) | Normotensive with RV dysfunction or elevated cardiac biomarkers | Moderate | Anticoagulation; escalate selectively |
| Low-risk | Normotensive with no RV dysfunction and normal biomarkers | Low | Anticoagulation alone |
4. Risk Factors for VTE
Virchow's Triad groups VTE risk into venous stasis, endothelial injury, and hypercoagulability.
| Category | Risk Factors |
|---|---|
| Venous stasis | Immobility, hospitalization, surgery, long travel, obesity, pregnancy, heart failure, venous insufficiency, advanced age |
| Endothelial injury | Trauma, fracture, surgery, central lines, pacemakers, atherosclerosis, vasculitis, prior VTE |
| Inherited hypercoagulability | Factor V Leiden, prothrombin mutation, antithrombin deficiency, protein C deficiency, protein S deficiency |
| Acquired hypercoagulability | Active cancer, pregnancy, estrogen therapy, HIT, antiphospholipid syndrome, nephrotic syndrome, inflammatory bowel disease |
5. VTE Prophylaxis
Every hospitalized patient should be assessed for VTE risk and receive prophylaxis if indicated and not contraindicated by bleeding risk.
Risk assessment models
- Padua score: medical inpatients
- Caprini score: surgical patients
Mechanical options
- Intermittent pneumatic compression
- Graduated compression stockings
- Use when pharmacologic prophylaxis is contraindicated
| Setting | Pharmacologic Prophylaxis | Mechanical Alternative |
|---|---|---|
| Medical inpatient | LMWH, UFH, or fondaparinux | IPC or compression stockings |
| Orthopedic surgery | LMWH, fondaparinux, selected DOACs, or warfarin | IPC until ambulatory |
| Major abdominal or pelvic surgery | LMWH, UFH, or fondaparinux | IPC |
| Major trauma or spinal cord injury | LMWH when feasible | IPC |
6. Diagnosis of VTE
DVT diagnostic approach
- Use Wells score to estimate pretest probability
- Negative D-dimer in low/intermediate probability can exclude DVT
- Compression ultrasound is first-line imaging
PE diagnostic approach
- Use Wells score for PE
- Negative D-dimer helps rule out PE in low-likelihood cases
- CT pulmonary angiography is the main definitive imaging test
- V/Q scan is an alternative in contrast allergy, pregnancy, or renal impairment
7. Anticoagulant Drug Classes
| 7.1. Unfractionated Heparin | Details |
|---|---|
| Mechanism | Potentiates antithrombin against thrombin and Factor Xa |
| Monitoring | aPTT or anti-Xa |
| Strengths | Rapid onset and offset, reversible, usable in renal impairment |
| Key risks | Bleeding, HIT, osteoporosis with long-term use |
| Reversal | Protamine sulfate |
| 7.2. Low Molecular Weight Heparins | Details |
|---|---|
| Examples | Enoxaparin, dalteparin, tinzaparin |
| Mechanism | Antithrombin-mediated Factor Xa inhibition greater than thrombin inhibition |
| Monitoring | Usually none; anti-Xa in special populations |
| Strengths | Predictable response, outpatient use, lower HIT risk than UFH |
| Limits | Renal clearance and only partial protamine reversal |
7.3. Fondaparinux
- Synthetic pentasaccharide with selective Factor Xa inhibition via antithrombin
- No HIT risk
- Contraindicated when CrCl is under 30 mL/min
- No specific reversal agent
7.4. Warfarin
- Vitamin K antagonist affecting II, VII, IX, X, proteins C and S
- Monitor INR; target 2-3 for VTE
- Needs overlap with parenteral anticoagulation during initiation
- Many drug and food interactions
| 7.5. Direct Oral Anticoagulants | Core Point |
|---|---|
| Rivaroxaban | Direct Factor Xa inhibitor; single-agent lead-in regimen |
| Apixaban | Direct Factor Xa inhibitor; single-agent lead-in regimen |
| Edoxaban | Direct Factor Xa inhibitor; requires parenteral lead-in |
| Dabigatran | Direct thrombin inhibitor; requires parenteral lead-in |
8. Treatment of VTE
8.1. Acute Phase Management
Goals are to prevent thrombus extension, embolization, recurrence, death, and long-term complications. Start anticoagulation promptly unless bleeding risk makes it unsafe.
| Strategy | Description | Examples |
|---|---|---|
| Single-agent DOAC | Start directly without parenteral lead-in, using higher initial doses | Rivaroxaban, apixaban |
| Parenteral lead-in to DOAC | Use LMWH, UFH, or fondaparinux for 5-10 days first | Edoxaban, dabigatran |
| Parenteral to warfarin | Overlap for at least 5 days and until INR is therapeutic | Warfarin |
8.2. Long-Term Management
Warfarin, DOACs, and LMWH are all options depending on cancer, pregnancy, renal function, mechanical valves, and access issues.
| 8.3. Duration of Anticoagulation | Typical Duration | Rationale |
|---|---|---|
| Provoked VTE | 3 months | Recurrence risk is relatively low after the transient trigger resolves |
| Unprovoked VTE | At least 3 months, often extended | Higher recurrence risk; balance with bleeding risk |
| Cancer-associated thrombosis | At least 3-6 months and often longer while cancer is active | High recurrence risk |
| Recurrent VTE | Often indefinite | Recurrence risk is high |
9. Special Populations
9.1. VTE in Pregnancy
- LMWH is preferred during pregnancy and postpartum
- Warfarin and DOACs are contraindicated during pregnancy
- Continue therapy at least 6 weeks postpartum and at least 3 months total
9.2. Cancer-Associated Thrombosis
- LMWH was the traditional standard
- DOACs are now accepted alternatives in many patients
- Bleeding risk is higher in GI and GU cancers
9.3. VTE in Renal Impairment
UFH and warfarin are the most flexible options in severe renal dysfunction. Fondaparinux and most DOACs should be avoided when renal impairment is severe.
9.4. VTE in Hepatic Impairment
Use caution in mild disease, avoid most DOACs in moderate disease, and prefer highly reversible strategies like UFH when hepatic impairment is severe and anticoagulation is unavoidable.
10. Reversal Agents
| 10.1. Vitamin K for Warfarin | Management |
|---|---|
| INR >4.5 with no bleeding | Hold warfarin; low-dose oral vitamin K may be considered |
| INR >10 with no bleeding | Hold warfarin and give oral vitamin K |
| Major bleeding | Give vitamin K 10 mg IV and 4-factor PCC |
10.2. PCC
4-factor PCC contains Factors II, VII, IX, and X plus proteins C and S and is preferred for rapid warfarin reversal. It may also be used off-label in DOAC-related bleeding when specific agents are unavailable.
10.3. Protamine Sulfate
Protamine fully reverses UFH, partially reverses LMWH, and does not reverse fondaparinux.
| 10.4. Specific DOAC Reversal Agents | Use |
|---|---|
| Andexanet alfa | Reverses Factor Xa inhibitors such as rivaroxaban and apixaban |
| Idarucizumab | Reverses dabigatran |
11. Peri-Procedural Management of Anticoagulation
Peri-procedural planning balances bleeding risk against thrombosis risk if anticoagulation is interrupted.
| Agent | Typical Interruption Before Procedure | Resumption |
|---|---|---|
| Warfarin | Hold about 5 days before high-risk procedures | Resume once hemostasis is secure, often same day or next day |
| DOACs | Usually hold 24 hours for lower risk and about 48 hours for higher risk procedures | Resume 24-48 hours after procedure if hemostasis is adequate |
| LMWH | Hold 12-24 hours for prophylactic dosing and longer for therapeutic dosing | Resume after adequate hemostasis |
12. Heparin-Induced Thrombocytopenia
HIT is an immune-mediated, prothrombotic complication of heparin therapy. UFH carries higher risk than LMWH.
Pathophysiology
- Heparin binds platelet factor 4
- IgG forms against the heparin-PF4 complex
- Platelets are activated through Fc receptors
- Thrombocytopenia occurs alongside thrombosis risk
| 4T's Category | Key Idea |
|---|---|
| Thrombocytopenia | Platelet fall greater than 50% is high-yield |
| Timing | Usually 5-10 days after exposure unless prior recent exposure |
| Thrombosis | New thrombosis raises the score |
| oTher causes | Absence of another cause raises suspicion |
13. Patient Counseling Points
For all anticoagulant patients
- Take doses exactly as prescribed
- Watch for bruising, prolonged bleeding, black stools, blood in urine, severe headache, or weakness
- Avoid starting OTC drugs, especially NSAIDs, without checking first
- Use a medical alert bracelet or carry anticoagulant identification
Drug-specific points
- Warfarin: keep vitamin K intake consistent and attend INR checks
- DOACs: do not double missed doses; rivaroxaban should be taken with food; dabigatran stays in original container
- LMWH: rotate abdominal injection sites and expect mild bruising
14. Summary for Exam Preparation
| Drug | Mechanism | Monitoring | Reversal | Key Use |
|---|---|---|---|---|
| UFH | AT-mediated Xa and IIa inhibition | aPTT / anti-Xa | Protamine | Acute VTE, renal impairment |
| LMWH | AT-mediated Xa greater than IIa inhibition | Anti-Xa in special situations | Partial protamine | VTE treatment, prophylaxis, pregnancy |
| Fondaparinux | AT-mediated Xa inhibition | Usually none | No specific agent | VTE, HIT option |
| Warfarin | Vitamin K antagonist | INR | Vitamin K, PCC | VTE, AF, mechanical valves |
| Rivaroxaban / Apixaban / Edoxaban | Direct Xa inhibition | None routine | Andexanet alfa | VTE and AF |
| Dabigatran | Direct thrombin inhibition | None routine | Idarucizumab | VTE and AF |
HIT
Think platelet drop greater than 50% about 5-10 days after heparin with paradoxical thrombosis.
DOAC Selection
Rivaroxaban and apixaban are rapid single-agent VTE options; edoxaban and dabigatran expect parenteral delay.
Warfarin Interactions
INR rises with amiodarone, antibiotics, and antifungals and falls with rifampin or high vitamin K intake.
15. Key Guidelines Links
CHEST Antithrombotic Therapy for VTE Disease 2021: https://journal.chestnet.org/article/S0012-3692(20)35259-6/fulltext
ASH VTE Management Guidance: https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines
ESC Acute PE Guideline 2019: https://academic.oup.com/eurheartj/article/41/4/543/5556137
ISTH DOAC Reversal Guidance 2021: https://onlinelibrary.wiley.com/doi/10.1111/jth.15387
NCCN Cancer-Associated VTE Guidance 2023: https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1452